The Bristol-Myers Squibb on Thursday reported quarterly results that exceeded expectations, but the 2025 guidance sent stocks low. Jim Cramer's faith in drug makers is unshakable. Analyst estimates compiled by LSEG show revenue for the fourth quarter increased 8% year-on-year to $12.34 billion, well above the $11.57 billion consensus. LSEG data shows an adjustment of $1.67, $1.67, for the three months ended December 31st. On an annual basis, adjusted EPS decreased by 1.8%. Bristol Myers Squibb (BMY) Why we own it: The company's new schizophrenia treatment Cobenfy has a huge potential for sale, but it remains an early inning. Bristol Myers has major products, including the blood preventive drug Eliquis and lung cancer therapy opdivo. However, we believe that the growth drug portfolio, including Cobenfy, will help you navigate its patent cliff. Started: November 25, 2024 Latest Purchase Date: January 17, 2025, Competitors: Abbabee, Pfizer, Amgen, Johnson & Johnson, Merck's Bottom Line Thursday Bristol Myers Stock Slide – Session Lows below 4.5% down over $57 – a gift for long-term investors. We repeat our ratings and price targets on par with our $70 per share purchase. Bristol-Myers shares were able to recover some later, dropping by around 2% in late-night morning trading. “It's shopping,” Jim told CNBC's “Squawk on the Street” Thursday morning. “I was praying for this [sell-off] Clubs cannot be purchased because we are restricted, but that doesn't stop us from telling our members what we do. Jim later said at a morning meeting, “You're Bmy 1y Mountain Bristol Myers squibb The heart of the Bristol Myers paper is Cobenfy, the company's new schizophrenia treatment that began in the US late last year. With fourth quarter sales of $10 million in revenues on Thursday, executives are pleased with the feedback they get from Cobenfy doctors and patients as well as the level of drug-secured insurance. So this is the first new mechanism of action in the treatment of schizophrenia. And we go out with our team to educate our customers about Cobenfy's differentiated profile, breaking reflexive prescribing habits, and That takes time,” Chief Commateriization Director Adam Lenkowsky said over the phone. Hopefully we will see a continuous strong intake until 2025, when the lamp is in the second half of this year. But together, we are truly delighted with what we've seen so far. And we plan to make this a huge product for the company over time. “Expanding the Cobenfy prescription label to include other conditions will help the drug recognize its commercial potential. This can drive higher inventory, including studies assessing the effects of Alzheimer's disease on psychosis, covering conditions such as bipolar disorder and autism disorder, at least one until the end of the decade. One clinical trial reiterated that Covenfee could become one of Bristol-Myers' overall guidance for 2025 certainly left something that was desired. The adjusted EPS guidance from $6.55 to $6.85 was lighter than the $6.92 consensus. However, there are several reasons to look at it after the mistake. The main one of them is that blood cancer treatment Revlimid is seeing an increase in general competition, which contributes to the gap between guidance and consensus. Jim said the company is very positive about the issue of Revlimid, so he isn't too worried. Another cancer treatment Pomalist is also working on expiring patents in Europe. In fact, executives say the “legacy drug” portfolio, which has concentrated exposure to patent expiration, is probably due to guidance mistakes that may not be burned down, coupled with a forex headwind of around $500 million. He said he called out. Analyst financial model. We also like that management has announced plans to cut costs by up to $2 billion by 2027. This is not the last time Bristol-Myers' patent cliff creates noise in the outcome, even if it is a well-documented part of the story. However, as long as Bristol Myers runs at the launch of Cobenfy and its broad “growth portfolio,” this continues to perform despite an increase in sales of 21% year-on-year in the quarter. You can continue working (Jim Kramer's Charitable Trust is long. See the full list of stocks before buying and selling stocks in the Charitable Trust portfolio, 45 minutes exemption after sending a trade alert Along with matters and disclaimers, our terms and conditions and privacy policy exist.
On July 22, 2022, a box of Bristol Myers Opgibo will be seen at the Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah.
George Frey | Reuters
Bristol Myers Squibb On Thursday, stocks with weaker guidance were reported, but stocks with better 2025 were lower. Jim Cramer's faith in drug makers is unshakable.
